Skip to main content

Table 2 Age-adjusted incidence rates and incidence rate ratios of small cell lung carcinoma and extrapulmonary small cell carcinoma according to primary site and stage, SEER-13, 1992-2010*

From: A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992–2010

 

Limited

Distant

Not specified

Distant-to-limited

Site

No.

IR

No.

IR

No.

IR

IRR

(95%CI)

Total

16,142

23.69

35,813

52.51

3,767

5.57

2.22

(2.18, 2.26)

SCLC

14,963

21.98

34,770

50.99

2,226

3.30

2.32

(2.28, 2.37)

EPSCC

1,179

1.71

1,043

1.52

216

0.31

0.89

(0.82, 0.97)

Salivary glands

37

0.06

16

0.02

<16

~

0.44

(0.23, 0.81)

Esophagus

73

0.11

93

0.14

21

0.03

1.27

(0.92, 1.75)

Stomach

22

0.03

53

0.08

<16

~

2.42

(1.45, 4.17)

Colon/rectum

76

0.11

152

0.22

<16

~

1.95

(1.47, 2.61)

Gallbladder

16

0.02

24

0.04

<16

~

1.48

(0.75, 2.97)

Pancreas

20

0.03

140

0.21

<16

~

6.87

(4.30, 11.61)

Breast (female)

47

0.12

21

0.05

<16

~

0.44

(0.25, 0.75)

Cervix

174

0.46

80

0.21

<16

~

0.46

(0.35, 0.60)

Uterus

28

0.07

25

0.07

<16

~

0.91

(0.51, 1.62)

Ovary

35

0.09

72

0.19

<16

~

2.11

(1.38, 3.25)

Prostate

66

0.23

108

0.38

32

0.11

1.62

(1.18, 2.25)

Urinary bladder

390

0.58

123

0.18

16

0.02

0.32

(0.26, 0.39)

  1. Abbreviations: CI confidence interval, EPSCC extrapulmonary small cell carcinoma, No. number of cases, SCLC small cell lung carcinoma, SEER-13 13 cancer registry areas of the Surveillance, Epidemiology and End Results (SEER) Program, ~ IRs are not calculated for <16 cases.
  2. *Incidence rates are age-adjusted to the 2000 U.S. standard population and expressed per 1,000,000 person-years. IRRs are based on unrounded rates. To allow a general overview of stage across primary sites, we used the SEER historic stage variable that includes localized (confined to the organ of origin), regional (direct extension to adjacent organ/tissue or regional lymph nodes), distant (discontinuous metastases), and unspecified stages. We combined localized and regional stages into the category of “limited” stage and maintained the distant stage variable as defined in the SEER Program.
  3. 95 % CI excludes 1.00 (based on unrounded upper and lower CI), and IRR is significant (P < 0.05).